Clinical Trials Browser

Dysgerminoma × Clear all

NCT03158064 2026-01-28

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Phase 2 Active not recruiting

Nonseminomatous germ cell tumor, Dysgerminoma, Neoplasms, Germ Cell and Embryonal, Germinoma, Seminoma

NCT06682078 2025-04-13

DEV-GEN-RiTuGo

Anorchia, Dysgerminoma, Gonadal Dysgenesis, Neoplasms, Disorders of Sex Development, Androgen-Insensitivity Syndrome, Gonadoblastoma

NCT01080521 2018-04-12

Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Teratoma, Ovarian, Brenner Tumor, Dysgerminoma, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00453310 2015-10-27

Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment

Phase 2 Completed

10 enrolled 6 charts

GenitourinaryGynecologic

Testicular Germ Cell Tumor, Dysgerminoma, Ovarian Neoplasms, Teratoma, Testicular Neoplasms, Carcinoma, Embryonal, Seminoma, Endodermal Sinus Tumor

NCT00313599 2014-07-02

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Dysgerminoma, Esophageal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Central Nervous System Neoplasms

NCT00042952 2013-01-17

Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

Phase 2 Terminated

Dysgerminoma, Testicular Neoplasms, Seminoma